NAVB - Navidea stock soars ~20% to get patents in US Japan

Navidea Biopharmaceuticals (NYSE:NAVB) said it received a Notice of Allowance for a U.S. patent application for diagnosis and treatment of leishmaniasis, a type of parasitic disease. Leishmaniasis is caused by infection with Leishmania parasites, which are spread via the bite of phlebotomine sand flies. The U.S. Patent Application No. 15/729,633 is titled 'Compounds And Compositions For Treating Leishmaniasis And Methods Of Diagnosis And Treating Using Same.' The company said the U.S. patent application protects the use of its mannosylated dextran-based drug-delivery vehicles to deliver small molecule therapeutic payloads as possible therapies for leishmaniasis. Navidea (NAVB) added that it has also received a Decision of Grant from the Japan Patent Office for the patent application No. 2020-107176. The Japanese patent application is titled 'Compounds And Compositions For Targeting Macrophages And Other Mannose-Binding C-Type Lectin Receptor High Expressing Cells And Methods Of Treating And Diagnosing Using Same.' The company noted that the Japanese application

For further details see:

Navidea stock soars ~20%, to get patents in US, Japan